



The 16th Annual Congress on Controversies in Ophthalmology: COPHy 2025  
April 4-5, Seville, Spain

COPHy 2025 – Preliminary Program as at September 15, 2024

<b>FRIDAY, APRIL 4, 2025</b>			
07:30-08:30	<b>Industry Sponsored Breakfast Symposium</b> <i>(Light breakfast will be served from 07:00-07:30 at the entrance of the hall)</i>		<b>HALL A</b>
08:30-10:00	<b>BIG CONTROVERSIES IN RETINA IN 2025</b>		<b>HALL A</b>
08:30-08:40	Welcome Remarks		
08:40-09:00	<b>Keynote Lecture: Retinal Implants to Restore Vision</b> Q&A		
09:00-09:30	<b>Debate 1: Complement inhibition is the best mechanistic approach to controlling geographic atrophy</b> YES / NO & Discussion		
09:30-10:00	<b>Debate 2: Gene Therapy for NVAMD will be the preferred therapy in the future</b> YES / NO & Discussion		
10:00-10:30	<b>Coffee Break, Visit Exhibition, View ePosters &amp; join us in the Speaker's Corner</b>		<b>EXHIBITION AREA</b>
	<b>HALL A</b>		<b>HALL B</b>
10:30-12:00	<b>MEDICAL RETINA 1   Neovascular ("Wet") AMD Management</b>		<b>10:30-12:00 GLAUCOMA 1</b>
10:30-11:00	<b>Debate 1: New generation anti-VEGF agents are specifically beneficial for pigment epithelial detachment</b> YES / NO & Discussion		<b>10:30-11:00 Debate 1: Phaco alone is better than Phaco Plus MIGS</b> YES / NO & Discussion
11:00-11:30	<b>Debate 2: Home monitoring has the potential to improve patient outcome in AMD</b> YES / NO & Discussion		<b>11:00-11:30 Debate 2: Clinicians decisions are better than AI decisions in Glaucoma</b> YES / NO & Discussion
11:30-12:00	<b>Debate 3: Surgical drug delivery of anti-VEGF has a potential to be a significant treatment option for neovascular AMD and other retinal diseases</b> YES / NO & Discussion		<b>11:30-12:00 Debate 3: Preventing Glaucoma is possible and feasible</b> YES / NO & Discussion
12:15-13:15	<b>Industry Sponsored Luncheon Symposium</b> <i>(Lunch boxes served 12:00-12:15)</i>		<b>HALL A</b>
13:30-14:30	<b>Industry-Sponsored Dessert Symposium</b> <i>(Dessert boxes served 13:15-13:30)</i>		<b>HALL A</b>
14:30-15:00	<b>Coffee Break, Visit Exhibition, View ePosters &amp; join us in the Speakers' Corner</b>		<b>EXHIBITION AREA</b>



The 16th Annual Congress on Controversies in Ophthalmology: COPHy 2025  
April 4-5, Seville, Spain

FRIDAY, APRIL 4, 2025			
	HALL A		HALL B
15:00-16:30	<b>SURGICAL RETINA 1   Controversial Approaches to Common Surgical Questions</b>	15:00-16:30	<b>GLAUCOMA 2</b>
15:00-15:30	<b>Debate 1: Inverted flap technique is the best surgical approach for large recurrent macular holes in high myopes</b> YES / NO & Discussion	15:00-15:30	<b>Debate 1: Should Glaucoma be managed by comprehensive ophthalmologists or Glaucoma specialists?</b> YES / NO & Discussion
15:30-16:00	<b>Debate 2: In the setting of a phakic macula-on retinal detachment, with a superior retinal tear, comparable successful anatomic and visual outcomes can be achieved with either a vitrectomy, or with a scleral buckle</b> YES / NO & Discussion	15:30-16:00	<b>Debate 2: Glaucoma drops should be Preservative Free from first line</b> YES / NO & Discussion
16:00-16:30	<b>Debate 3: Pars plana vitrectomy is safe and effective in the management of symptomatic vitreous floaters</b> YES / NO & Discussion	16:00-16:30	<b>Debate 3: What is the best first-line treatment for primary open angle Glaucoma?</b>
		16:00-16:10	<i>Position 1: Eye drops should be first-line treatment</i>
		16:10-16:20	<i>Position 2: SLT should be first-line treatment</i>
		16:20-16:30	<i>Position 3: MIGS should be first-line treatment</i>
16:30-17:30	<b>VISION ACADEMY IN RETINA 2025</b>		<b>HALL A</b>
17:30-18:30	<b>Industry Sponsored Symposium</b>		<b>HALL A</b>
18:30-19:30	<b>"Happy Hour" Cocktail</b>		<b>HALL A</b>
<b>End of Day</b>			



<b>SATURDAY, APRIL 5, 2025</b>			
<b>07:30-08:30</b>	<b>Industry Sponsored Breakfast Symposium</b> ( <i>Light breakfast will be served from 07:00-07:30 at the entrance of the hall</i> )		<b>HALL A</b>
	<b>HALL A</b>		<b>HALL B</b>
<b>08:30-10:00</b>	<b>MEDICAL RETINA 2   Diabetic Macular Edema (DME) and Proliferative Diabetic Retinopathy</b>	<b>08:30-10:00</b>	<b>NEURO-OPHTHALMOLOGY 1   The Afferent Pathway</b>
<b>08:30-09:00</b>	<b>Debate 1: Steroid Therapy for DME is still relevant in the Era of New Generation Anti-VEGF agents</b> YES / NO & Discussion	<b>08:30-09:00</b>	<b>Debate 1: All acute ON patients require high dose corticosteroids</b> YES / NO & Discussion
<b>09:00-09:30</b>	<b>Debate 2: Oral Therapy for NPDR will be adopted as primary approach to management of NPDR</b> YES / NO & Discussion	<b>09:00-09:30</b>	<b>Debate 2: Temporal artery (TA) ultrasound should replace TA biopsy in GCA</b> YES / NO & Discussion
<b>09:30-10:00</b>	<b>Debate 3: Novel topical steroids will become standard of care for initial therapy in mild DME</b> YES / NO & Discussion	<b>09:30-10:00</b>	<b>Case Presentations</b>
<b>10:00-10:30</b>	<b>Coffee Break, Visit Exhibition, View ePosters &amp; join us in the Speakers' Corner</b>		<b>EXHIBITION AREA</b>
<b>10:30-12:00</b>	<b>MEDICAL RETINA 3   Novel Technologies and Therapies in Retinal Diseases</b>	<b>10:30-12:00</b>	<b>UVEITIS 1</b>
<b>10:30-11:00</b>	<b>Debate 1: Multi-pathway or high dose inhibitors improve DME biomarkers more than previous treatments</b> YES / NO & Discussion	<b>10:30-11:00</b>	<b>Debate 1: The use of biosimilars in uveitis</b> YES / NO & Discussion
<b>11:00-11:30</b>	<b>Debate 2: Existing outcome measures are sufficient to demonstrate the efficacy of new therapies for inherited retinal diseases</b> YES / NO & Discussion	<b>11:00-11:30</b>	<b>Debate 2: Prophylactic laser retinopexy and early pars plana vitrectomy (PPV) for preventing retinal detachment (RD) in acute retinal necrosis</b> YES / NO & Discussion
<b>11:30-12:00</b>	<b>Debate 3: Blocking more than VEGFA can help in improving visual acuity in retinal disease</b> YES / NO & Discussion	<b>11:30-12:00</b>	<b>Debate 3: HLA - testing is mandatory in the investigation of posterior uveitis</b> YES / NO & Discussion
<b>12:15-13:15</b>	<b>Industry-Sponsored Luncheon Symposium</b> ( <i>Lunch boxes served 12:00-12:15</i> )		<b>HALL A</b>
<b>13:30-14:30</b>	<b>Industry-Sponsored Dessert Symposium</b> ( <i>Dessert boxes served 13:15-13:30</i> )		<b>HALL A</b>
<b>14:30-15:00</b>	<b>Coffee Break, Visit Exhibition, View ePosters &amp; join us in the Speakers' Corner</b>		<b>EXHIBITION AREA</b>



<b>SATURDAY, APRIL 5, 2025</b>			
<b>HALL A</b>		<b>HALL B</b>	
<b>15:00-16:30</b>	<b>SURGICAL RETINA 2   Controversies in the Utilization of Cutting Edge Vitreoretinal Surgical Technology</b>	<b>15:00-16:30</b>	<b>NEURO-OPHTHALMOLOGY 2   The Efferent Pathway</b>
<b>15:00-15:30</b>	<b>Debate 1: Artificial Intelligence (AI) can predict the success of retinal detachment surgery</b> YES / NO & Discussion	<b>15:00-15:30</b>	<b>Debate 1: Functional visual loss is an organic disease</b> YES / NO & Discussion
<b>15:30-16:00</b>	<b>Debate 2: Heavy silicone is the most beneficial adjuvant in the successful management of a retinal detachment with proliferative vitreoretinopathy (PVR)</b> YES / NO & Discussion	<b>15:30-16:00</b>	<b>Debate 2: IIH is a medical not surgical disease now...</b> YES / NO & Discussion
<b>16:00-16:30</b>	<b>Debate 3: Multifocal or Extended Depth of Focus (EDOF) IOLs can be employed after successful repair of a macula-off retinal detachment</b> YES / NO & Discussion	<b>16:00-16:30</b>	<b>Case Presentations</b>
<b>16:30-18:00</b>	<b>MEDICAL RETINA 4   New Treatment Strategies</b>	<b>16:30-18:00</b>	<b>UVEITIS 2</b>
<b>16:30-17:00</b>	<b>Debate 1: Functional outcomes need to be used for assessment of treatment effects of drugs for non neovascular Age Related Macular Degeneration</b> YES / NO & Discussion	<b>16:30-17:00</b>	<b>Debate 1: Systemic therapy is the best option to control uveitic macular edema</b> YES / NO & Discussion
<b>17:00-17:30</b>	<b>Debate 2: Photobiomodulation is a viable treatment in non neovascular AMD</b> YES / NO & Discussion	<b>17:00-17:30</b>	<b>Debate 2: Post-operative macular edema may be considered and managed as a uveitis</b> YES / NO & Discussion
<b>17:30-18:00</b>	<b>Debate 3: Complement inhibition for geographic atrophy has more benefit than risk</b> YES / NO & Discussion	<b>17:30-18:00</b>	<b>Debate 3: Inflammatory choroidal neovascularization may be treated by anti-VEGFs alone</b> YES / NO & Discussion
<b>End of Congress</b>			